论文部分内容阅读
目的分析总结静脉用药调配中心(PIVAS)在审方过程中审核出不合格处方的不合理原因,提出整改措施,提高处方合格率,促进临床安全合理用药。方法对PIVAS 2014年10月至2015年3月审核的肿瘤科和神经内科共5万多张电子处方中的66例不合理处方进行分类分析。结果不合理处方在调查的前3个月发生较多,分别达到33.33%、28.79%、16.67%,随着药师的严格审核,及时将发现的不合理处方反馈给临床医师,不合理处方逐月减少。构成比在10%以上的主要不合理因素包含:输液不成组(37.88%)、溶媒用量不当(21.21%)、溶媒选择不当(15.15%)及药物剂量不足(10.61%)。结论 PIVAS流程中药师的认真审核及与临床医师的有效沟通可减少临床的不合理用药,有效降低临床用药过程中不良事件的发生。
Objective To analyze and summarize the unreasonable causes of PIVAS during the trial process and propose corrective measures to improve the pass rate of prescriptions and promote the rational use of drugs in clinical practice. Methods The classification of 66 unreasonable prescriptions in more than 50,000 electronic prescriptions in oncology and neurology reviewed by PIVAS from October 2014 to March 2015 was analyzed. The unreasonable prescriptions occurred in the first 3 months of the survey, reaching 33.33%, 28.79% and 16.67% respectively. With the rigorous examination of the pharmacists, they timely reported the unreasonable prescriptions discovered to the clinicians to the clinician. cut back. The main irrational factors that make up more than 10% include: improper infusion (37.88%), improper dosage of solvent (21.21%), improper solvent selection (15.15%) and insufficient dosage of drug (10.61%). Conclusion The careful examination of pharmacists in the PIVAS process and effective communication with clinicians can reduce the irrational use of drugs and effectively reduce the incidence of adverse events during clinical medication.